InsiderTrades.com logo

COIL Insider Trading

Insider Ownership Percentage: 22.63%
Insider Buying (Last 12 Months): £8,548,725
Insider Selling (Last 12 Months): GBX 0

Roquefort Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Roquefort Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Roquefort Therapeutics Share Price & Price History

Current Price: GBX 9.10
Price Change: ▼ Price Decrease of -0.75 (-7.61%)
As of 04/10/2026 09:25 AM ET

This chart shows the closing price history over time for COIL up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Roquefort Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/21/2025Dr Darrin DisleyInsiderBuy500,000GBX 1,700£8,500,000
7/4/2025Stephen Paul WestInsiderBuy240,000GBX 20£48,000
6/27/2025Simon SinclairInsiderBuy7,250GBX 10£725
2/4/2025Stephen Paul WestInsiderBuy40,000GBX 30£12,000
8/1/2023Dr Darrin DisleyInsiderBuy26,993GBX 70£18,895.10
7/12/2023Stephen Paul WestInsiderBuy1,573GBX 60£943.80
6/26/2023Stephen Paul WestInsiderBuy14,411GBX 70£10,087.70
6/23/2023Trevor Ajanthan (Ajan) ReginaldInsiderBuy3,526GBX 70£2,468.20
See Full Table

SEC Filings (Institutional Ownership Changes) for Roquefort Therapeutics (LON:COIL)

1.74% of Roquefort Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Roquefort Therapeutics logo
Coiled Therapeutics (AIM: COIL) is an AIM-listed, clinical-stage biotechnology company focused on developing innovative precision oncology therapies. Its lead programme, AO-252, is a novel TACC3 inhibitor currently in Phase I clinical trials in the USA (trials ID: NCT06136884). Coiled Therapeutics is actively enrolling patients to test for safety and efficacy in patients whose cancer has progressed on other treatments. The Company is also assessing its STAT-6 siRNA programme for immunology indications. Coiled Therapeutics is supported by a leadership team with a proven track record in drug development and strategic backing from A2A Pharmaceuticals. https://coiledplc.com/
Read More on Roquefort Therapeutics

Today's Range

Now: GBX 9.10
Low: 8.55
High: 9.14

50 Day Range

MA: GBX 10.37
Low: 8.15
High: 14

52 Week Range

Now: GBX 9.10
Low: 8
High: 10

Volume

61,177 shs

Average Volume

203,610 shs

Market Capitalization

£38.75 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.05

Who are the company insiders with the largest holdings of Roquefort Therapeutics?

Roquefort Therapeutics' top insider investors include:
  1. Dr Darrin Disley (Insider)
  2. Simon Sinclair (Insider)
  3. Stephen Paul West (Insider)
  4. Trevor Ajanthan (Ajan) Reginald (Insider)
Learn More about top insider investors at Roquefort Therapeutics.